Keep pulling the thread on Novo Nordisk.
Novo Nordisk recently launched an oral pill version of Wegovy, which is the first oral GLP-1 obesity drug on the market.
In the bidding process for Metzera, Novo Nordisk's first and last bid was $10 billion, even after 16 total bids were made.
Pfizer ultimately acquired Metzera for approximately $10.1 billion after initially bidding $7 billion.
Novo Nordisk acquired Akerro for $5 billion to gain an asset for late-stage MASH (F4), a condition for which it previously had no treatment.
According to IQVIA data, the growth in direct-to-consumer (DTC) and cash-pay channels for obesity drugs is outpacing growth in traditional insured channels for both Novo Nordisk and Eli Lilly.
Out of 100 million people with obesity in the U.S., 55 million have insurance coverage for Wegovy, but only a low single-digit million are actually able to access the drug through their insurance.
Project Prometheus, a venture involving Bob Nelson, Vic Bajaj, and Jeff Bezos, is focused on using AI to interact with the physical world and is not a healthcare company.
Bob Nelson believes the biotech industry is overestimating the impact of AI in the short term (6-12 months) but underestimating its long-term impact, which could eliminate entire segments of the pharmaceutical industry.
Bob Nelson asserts that most doctors will eventually be replaced by AI, which he claims is already better than most of his own physicians.
The original ideas for nearly all of the 25 largest biopharma deals involving Chinese companies originated in the United States.
Over the past year, Novo Nordisk has been losing market share in the obesity treatment market to its competitor Eli Lilly.
Mike DuStar is the sixth CEO in Novo Nordisk's 103-year history and the first non-Danish person to hold the position.